Company: PTHS
Filing Date: 2025-05-27
Form Type: DEFM14C
Source: 0001140361-25-020509
Chunk: 7

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-05-27
Form: DEFM14C
Chunk 7
---
 STATEMENTS OF LNHC                                                            |     | F-49 |
| ANNEX A – MERGER AGREEMENT                                                                       |     |  A-1 |
| ANNEX B – PURCHASE AGREEMENT                                                                     |     |  B-1 |
| ANNEX C – NAME CHANGE CHARTER AMENDMENT                                                          |     |  C-1 |
| ANNEX D – AMENDED AND RESTATED 2023 PLAN                                                         |     |  D-1 |

vi

TABLE OF CONTENTS

|                                                                                            |     | Page |
| ANNEX E – WRITTEN CONSENT                                                                  |     | E-1  |
| ANNEX F – FAIRNESS OPINION                                                                 |     | F-1  |
| ANNEX G – FORM OF LOCK-UP (CERTAIN INVESTORS WHO HAVE ENTERED INTO THE PURCHASE AGREEMENT) |     | G-1  |
| ANNEX H – FORM OF LOCK-UP (CERTAIN INVESTMENT COMPANY)                                     |     | H-1  |
| ANNEX I – FORM OF LOCK-UP AGREEMENT (NOMIS BAY, LIGAND AND OTHER INVESTORS)                |     | I-1  |
| ANNEX J – FORM OF REGISTRATION RIGHTS AGREEMENT                                            |     | J-1  |
| ANNEX K – REVERSE STOCK SPLIT CHARTER AMENDMENT                                            |     | K-1  |

Certain schedules and exhibits from certain Annexes have been omitted. Channel agrees to furnish supplementally a copy of such schedules and exhibits, or any section thereof, to the SEC upon its request.

vii

#### TABLE OF CONTENTS

### SUMMARY
This summary highlights selected information in this information statement and may not contain all of the information about the Transaction that is important to you. You should carefully read this information statement in its entirety, including the annexes hereto and the other documents to which we have referred you, for a more complete understanding of the Transaction. You may obtain, without charge, copies of documents incorporated by reference into this information statement by following the instructions under the section entitled “Where You Can Find Additional Information” beginning on page 285 .

#### The Companies

#### Channel Therapeutics Corporation

#### 4400 Route 9 South, Suite 1000

#### Freehold, NJ 07728
(877) 265-8266

Channel is a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to